Beautiful Virgin Islands

Tuesday, Jun 24, 2025

Everything you need to know about Pfizer’s COVID-19 vaccine

Everything you need to know about Pfizer’s COVID-19 vaccine

Reported breakthrough in race to find coronavirus vaccine welcomed by scientists and leaders, but experts caution many questions remain.

Raising hopes for a major victory in the fight against the coronavirus pandemic, drugmakers Pfizer and BioNTech have said their experimental vaccine may be 90 percent effective at preventing COVID-19.

The announcement on Monday reverberated across the world, with stock markets surging to new records and political leaders welcoming the late-stage trial results – even as scientists and doctors cautioned many questions remained unanswered and warned any celebration would be premature.

As the efforts to contain a disease that has killed more than 1.25 million people and ravaged livelihoods globally, here is all you need to know about the promising vaccine.

What was announced?


The drugmakers’ trial involves some 44,000 people in six countries, half of whom have been administered with the vaccine, while the other half were given a placebo – a treatment designed to have no effect.

Monday’s data is from an interim analysis that was conducted after 94 participants in the continuing trial developed COVID-19. Fewer than nine of them who caught the disease had been given the vaccine.

To confirm the efficacy rate, Pfizer said it would continue its trial until there were 164 COVID-19 cases among volunteers, a number that the Food and Drug Administration (FDA) has agreed is enough to tell how well the vaccine is working.

The data, however, have yet to be peer-reviewed or published in a medical journal. Pfizer said it would do so once it has the results from the entire trial.

Outside experts said key details of the data need to be analysed and cautioned that many questions remain, including whether the vaccine can prevent severe disease or complications, how long it will protect against infection and how well it will work in the elderly.

How does this vaccine work?


When you get vaccinated, you are usually given either a weakened or a dead part of the virus, or the bacteria that causes an illness. In this way, the vaccine does not make you ill, but your body recognises that it is a foreign element and it mounts an immune response. This means that when your body comes across the real bug that causes that illness, it will be ready to attack it straight away.

The way this new vaccine works is called mRNA, meaning that you are not actually being injected with parts of the virus or a weakened form of it, but you are actually being administered with a part of the genetic code of the coronavirus. This tricks the body into producing some of the viral proteins itself so that the immune system then detects these proteins and starts to produce a defensive response to them.

What was the reaction?


Investors piled into banks stocks, airlines and other economically sensitive companies that had been battered by months of coronavirus-led lockdowns and travel bans, pushing major US stock indexes to fresh record highs.

Pfizer shares were indicated 6 percent higher in New York, while BioNTech’s US stock leapt 18 percent.

The World Health Organization said the results were very positive, but warned there was a funding gap of $4.5bn that could slow access to tests, medicines and vaccines in low- and middle-income countries.

Experts also warned there could be major challenges in distributing the vaccine, especially in poorer countries where power supplies are inadequate, as it must be stored at industrial deep-freeze temperatures to be effective.

What’s next?


Pfizer and BioNTech said they plan to apply to the FDA for emergency approval to use the vaccine by the end of the month, when they will have two months of safety data on about half of trial participants. This has raised the possibility of a regulatory decision as soon as December.

To save time, the companies began manufacturing the vaccine before they knew whether it would be effective. They now expect to produce up to 50 million doses, or enough to protect 25 million people, this year.

Pfizer said it expects to produce up to 1.3 billion doses of the vaccine in 2021.

Who is lining up to buy it?


Pfizer and BioNTech have a $1.95bn contract with the US government to deliver 100 million vaccine doses beginning this year. They have also reached supply agreements with the European Union, the United Kingdom, Canada and Japan.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Macron and Merz: Europe must arm itself in an unstable world
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Airlines Evaluate Flight Cancellations Amid Escalating US-Iran Tensions
Starmer Invites Innovators to Join Government Talent Scheme
UK Economy’s Strong Opening Quarter Shows Signs of Cooling
Harrods Seeks Court Order to Secure Al Fayed Estate for Victims
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
Labubu Doll Drives Pop Mart to Status as China’s Most Valuable Toy Maker
Global Coal Demand Defies Paris Accord Goals
We have new information and breaking details to share about what is shaping up to be a historic air campaign tonight
Six Massive Bombs Dropped on Fordow; Trump: 'A Historic Moment for the U.S., Israel, and the World'
Fordow: Deeply Buried Iranian Enrichment Site in U.S.–Israel Crosshairs
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Pakistan to nominate Trump for Nobel Peace Prize.
BBC Demands Perplexity AI Immediately Stop Using Its Content
Telegram Founder: I Will Leave My Fortune to Over 100 of My Children
Political Turmoil Resurfaces in Belgium Amid Economic Concerns
Fed policymakers divided on timing of interest rate cuts
Trump signals imminent agreement with Harvard University
Inheritance tax referendum alarms Swiss billionaire community
Japan cancels bilateral security meeting amid US defence demands
AI skeptic Emily Bender warns that ‘the emperor has no clothes’
Israel Confirms Assassination of Quds Force Commander in Tehran
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
FBI and Senate Investigate Allegations of Chinese Plot to Influence the 2020 Election in Biden’s Favor Using Fake U.S. Driver’s Licenses
Vietnam Emerges as Luxury Yacht Destination for Ultra‑Rich
Plans to Sell Dutch Embassy in Bangkok Face Local Opposition
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump's $5 Million 'Trump Card' Visa Program Draws Nearly 70,000 Applicants
DGCA Finds No Major Safety Concerns in Air India's Boeing 787 Fleet
Airlines Reroute Flights Amid Expanding Middle East Conflict Zones
Elon Musk's xAI Seeks $9.3 Billion in Funding Amid AI Expansion
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Israeli Airstrike Targets Iranian State TV in Central Tehran
President Trump is leaving the G7 summit early and has ordered the National Security Council to the Situation Room
Taiwan Imposes Export Ban on Chips to Huawei and SMIC
Israel has just announced plans to strike Tehran again, and in response, Trump has urged people to evacuate
Netanyahu Signals Potential Regime Change in Iran
Juncker Criticizes EU Inaction on Trump Tariffs
EU Proposes Ban on New Russian Gas Contracts
×